{
  "docId": "019de073-dc46-770c-87a2-2b21d91043e5",
  "docSlug": "4f9fcbb83e828aea5419518c9cca9ae9",
  "documentTitle": "Tonix Pharmaceuticals | Investor Presentation Deck | 29 slides",
  "authorId": "tonix-pharmaceuticals",
  "authorName": "Tonix Pharmaceuticals",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 29,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "other",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "Slide provides a high-level summary of a pharmaceutical asset's profile and development roadmap.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de073-dc46-770c-87a2-2b21d91043e5/15",
  "deckHref": "/decks/019de073-dc46-770c-87a2-2b21d91043e5",
  "deckJsonHref": "/decks/019de073-dc46-770c-87a2-2b21d91043e5.json",
  "deckAnchorHref": "/decks/019de073-dc46-770c-87a2-2b21d91043e5#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.45,
        "x": 0.52,
        "y": 0.25
      },
      "kind": "list",
      "text": "Market Entry: Chronic Migraine. Additional Indications: Acute Migraine, Craniofacial Pain, Insulin Resistance, Binge Eating Disorder. Status: Phase 2 ready. Next Steps: 4Q 2022 Initiate Phase 2 Trial and Investigator Initiated Phase 2 Trial in Binge Eating Disorder.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "28248ad6-73e2-444d-9450-2f8387e28048",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "list",
      "text": "Intranasal OT has potential utility in treating migraine. Intranasal OT reaches the trigeminal ganglion. Preclinical evidence of OT blocking CGRP release and suppressing pain. Association of low OT levels during and preceding migraine episodes.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a2667d60-3d9f-4f22-9d21-e6b74ed6bec1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.45,
        "x": 0.05,
        "y": 0.55
      },
      "kind": "paragraph",
      "text": "Magnesium is known to potentiate the binding of OT to its receptor. One billion individuals worldwide suffer from migraines. Differentiator: Novel non-CGRP antagonist approach to treatment.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "983921a4-b4aa-4baa-8133-e631ec05118e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.52,
        "y": 0.82
      },
      "kind": "source-note",
      "text": "TNX-1900 has not been approved for any indication. CGRP = calcitonin gene-related peptide.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f94862e9-b2a5-4112-bfc6-6b6de7f08c06",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.65,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "TNX-1900*: Migraine Intranasal Potentiated Oxytocin (OT) with Magnesium",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9a223525-0dd9-4370-9dea-6dfa286cf81f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Audience Definition",
      "slug": "audience-definition",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "65ba9764-2fb0-4a24-98ef-7a034c884f0c",
      "evidence": "list/bullet: Market Entry: Chronic Migraine. Additional Indications: Acute Migraine, Craniofacial Pain, Insulin Resistance, Binge Eating Disorder.",
      "confidence": 0.7
    },
    {
      "name": "Problem Statement Canvas",
      "slug": "problem-statement-canvas",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "58fd7cd9-9390-4b77-8d1e-af9e24546b57",
      "evidence": "paragraph/paragraph: One billion individuals worldwide suffer from migraines.",
      "confidence": 0.6
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 15,
      "from": 7,
      "beatId": "7e5647ed-6856-422f-b350-52485c939d0b",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The presentation outlines the company's product candidates and their potential applications",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 29,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "e532f435-d20e-4323-8595-44dab22c3ce1",
      "evidence": "The presentation uses a golden circle structure to communicate the company's mission and vision",
      "position": 0,
      "objective": "Why Tonix Pharmaceuticals?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}